Aimovig (CGRP monoclonal antibody) is approved by the FDA!

May 18, 2018

Yesterday the FDA approved the long-awaited breakthrough drug for the prevention of migraines. It promises to provide relief to two out of three migraine sufferers with minimal side effects.

It should become available in a couple of weeks. The cost of the monthly injection is $575, but hopefully most insurance plans will cover it. The insurance companies are likely to require that the patient first try and fail a couple of inexpensive drugs before paying for Aimovig, as they do with Botox.

The medicine comes in a simple-to-use auto-injector and after the initial injection patients will be able to self-administer it.

To patients of the New York Headache Center – please call the office and schedule an appointment.

Written by
Alexander Mauskop, MD